{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T18:48:33Z","timestamp":1782154113156,"version":"3.54.5"},"update-to":[{"DOI":"10.1371\/journal.pntd.0014449","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000}}],"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"\n Background<\/jats:title>\n Albendazole is a broad-spectrum anthelminthic extensively used in clinical settings and national deworming programs. It is the cornerstone of the preventive chemotherapy for soil-transmitted helminthiases prevalent in low-resource settings. The high proliferation of albendazole generic products, with poor post-market surveillance capacity in the low- and middle-income countries, poses dire risk of substandard and falsified medicines, which may predispose patients to treatment failures, adverse drug reactions, morbidity, and mortality, with consequent loss of public confidence in healthcare systems.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This study aimed to determine the quality and pharmaceutical equivalence of albendazole 400 mg tablet brands marketed in Nairobi, Kenya.<\/jats:p>\n <\/jats:sec>\n \n Experimental<\/jats:title>\n \n A cross-sectional analytical study was conducted on seven albendazole 400 mg tablet brands purchased from pharmacy outlets in Nairobi. Tests for identity, friability, hardness, disintegration, assay, uniformity of weight, and dissolution were conducted as specified in the United States, British and International Pharmacopoeias. Dissolution profiles of generic albendazole tablet brands and the innovator brand (Zentel) were compared using model independent fit factors\n f<\/jats:italic>\n \n 1<\/jats:italic>\n <\/jats:sub>\n and\n f<\/jats:italic>\n \n 2<\/jats:italic>\n <\/jats:sub>\n , and the dissolution efficiency (DE). Data was captured and analyzed using Microsoft Excel 2021, and reported as means, relative standard deviations, and percentages.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n All the seven albendazole 400 mg tablet brands complied with compendial specifications for identity, friability, hardness, assay, and uniformity of weight. However, two brands (EK5 and EK6) did not comply with the disintegration test and consequently demonstrated extremely poor dissolution, having released <6% of labelled albendazole content at 60 minutes with DE\u2009<\u20095%. Only two brands (EK4 and EK2) exhibited dissolution profiles that approximated the innovator brand (\n f<\/jats:italic>\n \n 2<\/jats:italic>\n <\/jats:sub>\n \u2009>\u200950,\n f<\/jats:italic>\n \n 1<\/jats:italic>\n <\/jats:sub>\n \u2009\n <<\/jats:italic>\n \u200910) and could be used interchangeably, while the other two (EK3 and EK7) had intermediate drug release.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n While all tested albendazole 400 mg tablet brands complied with basic pharmacopoeial specifications for quality, dissolution testing revealed significant nonequivalence, with only three (42.86%) of the seven brands being pharmaceutically equivalent. Poor dissolution of majority (57.14%) of albendazole tablet brands portends therapeutic insufficiency and development of drug resistance, reinforcing the need for stringent post-market surveillance to safeguard public health.<\/jats:p>\n <\/jats:sec>","DOI":"10.1371\/journal.pntd.0014449","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:39:55Z","timestamp":1781631595000},"page":"e0014449","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Post-market surveillance of albendazole tablet brands in Kenya: Implications for deworming programs and clinical outcomes"],"prefix":"10.1371","volume":"20","author":[{"given":"Ezra Kiprono","family":"Yator","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6321-1022","authenticated-orcid":true,"given":"Peter Mbugua","family":"Njogu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"issue":"10117","key":"pntd.0014449.ref001","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0140-6736(17)31930-X","article-title":"Soil-transmitted helminth infections","volume":"391","author":"PM Jourdan","year":"2018","journal-title":"Lancet"},{"issue":"8","key":"pntd.0014449.ref002","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000412","article-title":"Neglected tropical diseases in sub-saharan Africa: review of their prevalence, distribution, and disease burden","volume":"3","author":"PJ Hotez","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"pntd.0014449.ref003","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s40249-024-01238-9","article-title":"Global burden of soil-transmitted helminth infections, 1990-2021","volume":"13","author":"J Chen","year":"2024","journal-title":"Infect Dis Poverty"},{"issue":"3","key":"pntd.0014449.ref004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001620","article-title":"Water, sanitation, hygiene, and soil-transmitted helminth infection: a systematic review and meta-analysis","volume":"11","author":"EC Strunz","year":"2014","journal-title":"PLoS Med"},{"issue":"10","key":"pntd.0014449.ref005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008604","article-title":"Prevalence, intensity and associated risk factors of soil-transmitted helminth and schistosome infections in Kenya: Impact assessment after five rounds of mass drug administration in Kenya","volume":"14","author":"C Okoyo","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"pntd.0014449.ref006","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(20)30398-3","article-title":"Prevalence and intensity of soil-transmitted helminth infections of children in sub-Saharan Africa, 2000\u201318: a geospatial analysis","volume":"9","author":"B Sartorius","year":"2021","journal-title":"Lancet Glob Health"},{"issue":"3","key":"pntd.0014449.ref007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003895","article-title":"Eliminating the Neglected Tropical Diseases: Translational Science and New Technologies","volume":"10","author":"PJ Hotez","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"pntd.0014449.ref008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0011043","article-title":"Precision mapping of schistosomiasis and soil-transmitted helminthiasis among school age children at the coastal region, Kenya","volume":"17","author":"S Kepha","year":"2023","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"pntd.0014449.ref009","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/trstmh\/trx082","article-title":"Preventive chemotherapy to control soil-transmitted helminthiasis averted more than 500 000 DALYs in 2015","volume":"111","author":"A Montresor","year":"2017","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"4","key":"pntd.0014449.ref010","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/0169-4758(90)90232-S","article-title":"Use of benzimidazole chemotherapy in human helminthiases: indications and efficacy","volume":"6","author":"GC Cook","year":"1990","journal-title":"Parasitol Today"},{"issue":"5","key":"pntd.0014449.ref011","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.bbagen.2011.12.013","article-title":"Mitochondrial fumarate reductase as a target of chemotherapy: from parasites to cancer cells","volume":"1820","author":"C Sakai","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"pntd.0014449.ref012","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/B978-0-323-55512-8.00162-9","article-title":"Albendazole.","volume-title":"Hunter\u2019s Tropical Medicine and Emerging Infectious Diseases","author":"AK Bloom","year":"2020","edition":"10"},{"key":"pntd.0014449.ref013","unstructured":"World Health Organization. Substandard and falsified medical products. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/substandard-and-falsified-medical-products"},{"issue":"3","key":"pntd.0014449.ref014","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jmgm.2004.08.001","article-title":"A possible model of benzimidazole binding to beta-tubulin disclosed by invoking an inter-domain movement","volume":"23","author":"MW Robinson","year":"2004","journal-title":"J Mol Graph Model"},{"issue":"1","key":"pntd.0014449.ref015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0295956","article-title":"Substandard and falsified antimicrobials in selected east African countries: A systematic review","volume":"19","author":"AA Tegegne","year":"2024","journal-title":"PLoS One"},{"issue":"10","key":"pntd.0014449.ref016","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/14740338.2023.2251375","article-title":"Drug safety in Africa: a review of systems and resources for pharmacovigilance","volume":"22","author":"HB Ndagije","year":"2023","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"pntd.0014449.ref017","doi-asserted-by":"crossref","first-page":"105","DOI":"10.4314\/ecajps.v25i3.3","article-title":"Quality evaluation of ciprofloxacin, metronidazole, albendazole tablets and amoxicillin suspension, marketed in Mwanza, Tanzania: A cross sectional study","volume":"25","author":"E Kimaro","year":"2024","journal-title":"ecajps"},{"issue":"1","key":"pntd.0014449.ref018","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s40360-024-00774-2","article-title":"Modeling and comparison of dissolution profiles for different brands of albendazole boluses","volume":"25","author":"YT Mekasha","year":"2024","journal-title":"BMC Pharmacol Toxicol"},{"issue":"9","key":"pntd.0014449.ref019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004057","article-title":"Assessment of Efficacy and Quality of Two Albendazole Brands Commonly Used against Soil-Transmitted Helminth Infections in School Children in Jimma Town, Ethiopia","volume":"9","author":"S Belew","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"pntd.0014449.ref020","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"GL Amidon","year":"1995","journal-title":"Pharm Res"},{"key":"pntd.0014449.ref021","article-title":"Albendazole chewable tablets.","volume-title":"The International Pharmacopoeia","author":"World Health Organization","year":"2025","edition":"13"},{"key":"pntd.0014449.ref022","volume-title":"British pharmacopoeia. Vol. III","author":"British Pharmacopoeia Commission","year":"2004"},{"key":"pntd.0014449.ref023","article-title":"Albendazole tablets.","volume-title":"The United States Pharmacopeia\u2013The National Formulary, Vol. 48(5)","author":"United States Pharmacopeial Convention","year":"2005"},{"key":"pntd.0014449.ref024","unstructured":"US Food and Drug Administration. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a Biopharmaceutics Classification System. Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm070246.pdf"},{"issue":"6","key":"pntd.0014449.ref025","first-page":"64","article-title":"Mathematical comparison of dissolution profiles","volume":"20","author":"JW Moore","year":"1996","journal-title":"Pharm Tech"},{"issue":"1","key":"pntd.0014449.ref026","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1080\/10543406.2015.1092027","article-title":"Some thoughts on drug interchangeability","volume":"26","author":"S-C Chow","year":"2016","journal-title":"J Biopharm Stat"},{"key":"pntd.0014449.ref027","doi-asserted-by":"crossref","DOI":"10.1590\/s2175-97902023e23171","article-title":"Analysis of the effect of in vitro dissolution on the pharmacokinetics of albendazole","volume":"59","author":"N Castro","year":"2023","journal-title":"Braz J Pharm Sci"},{"issue":"1","key":"pntd.0014449.ref028","doi-asserted-by":"crossref","first-page":"46","DOI":"10.20428\/yjms.v11i1.1223","article-title":"Quality Assessment of Seven Brands of Albendazole Tablets Marketed in Yemen","volume":"11","author":"GQ Othman","year":"2018","journal-title":"Yemeni J Med Sci"},{"issue":"12","key":"pntd.0014449.ref029","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1023\/A:1018907527253","article-title":"Albendazole generics--a comparative in vitro study","volume":"16","author":"E Galia","year":"1999","journal-title":"Pharm Res"},{"issue":"1","key":"pntd.0014449.ref030","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1208\/s12249-021-02203-7","article-title":"Simplified Model-Dependent and Model-Independent Approaches for Dissolution Profile Comparison for Oral Products: Regulatory Perspective for Generic Product Development","volume":"23","author":"S Kollipara","year":"2022","journal-title":"AAPS PharmSciTech"},{"key":"pntd.0014449.ref031","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/B978-0-12-802103-3.00021-3","article-title":"Generic drug and bioequivalence studies.","volume-title":"Pharmaceutical Medicine and Translational Clinical Research","author":"RK Jalali","year":"2018"},{"key":"pntd.0014449.ref032","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/B978-0-444-53242-8.00015-1","article-title":"Bioavailability and bioequivalence.","volume-title":"Developing solid oral dosage forms: Pharmaceutical theory and practice","author":"H Zhu","year":"2009"},{"issue":"8","key":"pntd.0014449.ref033","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s11095-025-03892-6","article-title":"Dissolution Profiles Comparison Using Various Model Independent Statistical Approaches: Can We Increase Chance of Similarity?","volume":"42","author":"R Boddu","year":"2025","journal-title":"Pharm Res"},{"issue":"10","key":"pntd.0014449.ref034","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3390\/pharmaceutics13101703","article-title":"A Critical Overview of FDA and EMA Statistical Methods to Compare In Vitro Drug Dissolution Profiles of Pharmaceutical Products","volume":"13","author":"J Musel\u00edk","year":"2021","journal-title":"Pharmaceutics"},{"issue":"4","key":"pntd.0014449.ref035","doi-asserted-by":"crossref","first-page":"15","DOI":"10.14227\/DT040497P15","article-title":"fDA Guidance for Industry 1 Dissolution Testing of Immediate Release Solid Oral Dosage Forms","volume":"4","author":"VP Shah","year":"1997","journal-title":"Dissolution Technol"},{"key":"pntd.0014449.ref036","volume-title":"Guideline on the investigation of bioequivalence","author":"European Medicines Agency Committee for Medicinal Products for Human Use","year":"2010"},{"key":"pntd.0014449.ref037","unstructured":"Food & Drug Administration. FDA guidance for industry: Quality attribute considerations for chewable tablets. Available from: Quality Attribute Considerations for Chewable Tablets Guidance for Industry. Accessed 10 May 2026."},{"key":"pntd.0014449.ref038","unstructured":"United Nations. Sustainable Development Goals 2015\u20132030. Goal 3: Ensure healthy lives and promote well-being for all at all ages. New York: United Nations; 2015. Available from Goal 3 | Department of Economic and Social Affairs. Accessed 7 June 2025."}],"updated-by":[{"DOI":"10.1371\/journal.pntd.0014449","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000}}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0014449","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T18:00:16Z","timestamp":1782151216000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0014449"}},"subtitle":[],"editor":[{"given":"Sabine","family":"Specht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":38,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0014449","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]}}}